KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Interest & Investment Income (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Interest & Investment Income data on record, last reported at $121.9 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 4.91% year-over-year to $121.9 million; the TTM value through Dec 2025 reached $490.9 million, down 17.92%, while the annual FY2025 figure was $490.9 million, 17.92% down from the prior year.
  • Interest & Investment Income reached $121.9 million in Q4 2025 per VRTX's latest filing, down from $125.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $181.2 million in Q1 2024 and bottomed at $1.1 million in Q2 2021.
  • Average Interest & Investment Income over 5 years is $92.7 million, with a median of $122.2 million recorded in 2025.
  • Peak YoY movement for Interest & Investment Income: crashed 88.07% in 2021, then surged 7562.5% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $1.2 million in 2021, then skyrocketed by 7066.67% to $86.0 million in 2022, then surged by 108.72% to $179.5 million in 2023, then fell by 28.58% to $128.2 million in 2024, then decreased by 4.91% to $121.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $121.9 million in Q4 2025, $125.7 million in Q3 2025, and $122.4 million in Q2 2025.